

A prospective, multicentre, open label, exploratory study to investigate the ability of the Heidelberg assay panel and the B-Cell /antibody response panel to predict the clinical effect of Octagam® 5% in subjects with relapsing/remitting multiple sclerosis

Submission date 18/03/2009	Recruitment status No longer recruiting	☒ Prospectively registered
Registration date 18/03/2009	Overall study status Completed	☐ Protocol
Last Edited 10/04/2013	Condition category Nervous System Diseases	☐ Statistical analysis plan
		☐ Results
		☐ Individual participant data
		☐ Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Stefan Wietek

Contact details
Octapharma PPG
Vienna CR&D Office
Oberlaaer Str. 235
Vienna
Austria
1100
+43 (0)1 61032 1778
stefan.wietek@octapharma.com

Additional identifiers

Protocol serial number

Study information

Scientific Title

Study objectives

To find a panel of laboratory parameters which might be able to predict the clinical outcome of treatment of patients with relapsing-remitting multiple sclerosis (MS) with Octagam®.

Ethics approval required

Old ethics approval format

Ethics approval(s)

1. EC Medical University of Innsbruck (Austria) - includes approval for Linz and Klagenfurt; approval received on the 9th January 2009 and final approval for additional study materials received on 22nd January 2009
2. EC Heidelberg (Germany) - includes approval for study sites at Heidelberg, Asbach, Berlin, Hamburg, Regensburg, Rostock; approval received on the 31st March 2009

Study design

Prospective exploratory open label multicentre phase II trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Multiple sclerosis

Interventions

Octagam® 5% (12 infusions 0.4 g/kg every 4 weeks).

Intervention Type

Other

Phase

Phase II

Primary outcome(s)

A panel of lab parameters (components of cells of the immune system, serum proteins, gene expression, single nucleotide polymorphism [SNP] analysis) will be analysed at baseline, 12 - 24 hours after end of the first infusion, and 24 and 48 weeks after the first Octagam® administration and the clinical course of the disease will be monitored by relapse activity, EDSS and Multiple Sclerosis Functional Composite (MSFC) at predefined time points. Statistical

analysis will test whether any of the lab parameters of the HAP panel or the B-cell antibody response panel might be able to predict the clinical outcome observed following Octagam® 5% treatment. The proportion of subjects clinically responding to Octagam® 5% will be determined.

Key secondary outcome(s)

Lesion load in brain MRI imaging (T2 weighted, T1 weighted, Gd-enhancing lesion load) after treatment will be compared to lesion load before treatment.

Completion date

20/09/2010

Eligibility**Key inclusion criteria**

1. Subjects aged greater than or equal to 18 years, either sex
2. Multiple sclerosis (MS) according to the revised McDonald criteria
3. Relapsing-remitting form of MS
4. First-line disease modifying treatments (interferon-beta [IFN-beta] or glatiramer acetate) are contraindicated or not tolerated
5. Kurtzke's Expanded Disability Status Scale (EDSS) between 0 and 3.5 (0 to less than 3.5)
6. Subjects who experienced at least one relapse during the last 12 months or at least two relapses in the last 24 months prior to study entry
7. Freely given, fully informed written consent obtained from subject

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Subjects who have received treatment with immunoglobulins for any reason previously
2. Subjects who have received immuno-suppressive treatments (e.g. azathioprine, mitoxantrone, cyclophosphamide) for any reason previously except relapse treatment with corticosteroids
3. Subjects who have received disease modifying first-line treatments with IFN-beta during the last 8 weeks or with glatiramer acetate during the last 16 weeks
4. Subjects who have received any monoclonal antibody therapies (e.g. natalizumab) previously
5. Subjects who had a relapse within 3 months prior to study entry
6. Subjects with severe renal function impairment as defined by serum creatinine values greater than 24 mg/l
7. Subjects with known intolerance to homologous immunoglobulins, especially immunoglobulin

A (IgA) deficiency, when the subject has antibodies against IgA

8. Subjects with a body weight of greater than 120 kg

9. Subjects with a history of anaphylaxis after previous transfusions of blood or blood products

10. Subjects for whom magnetic resonance imaging (MRI) is contraindicated or who are allergic to gadolinium

11. Pregnant or lactating women

12. Subjects who delivered a baby within 12 months before study entry (including miscarriage and stillbirth)

13. Subjects with a diagnosis of significant depression

14. Subjects with known chronic infectious diseases or malignant disease

15. Subjects with known antibody deficiencies or other autoimmune diseases other than MS

16. Subjects participating in another study during the course of this study or during the past 6 months or who have ever participated in a study investigating in new disease modifying or immunosuppressive drugs

Date of first enrolment

20/03/2009

Date of final enrolment

20/09/2010

Locations

Countries of recruitment

Austria

Germany

Study participating centre

Octapharma PPG

Vienna

Austria

1100

Sponsor information

Organisation

Octapharma AG (Switzerland)

ROR

<https://ror.org/002k5fe57>

Funder(s)

Funder type

Industry

Funder Name

Octapharma AG (Switzerland)

Results and Publications

Individual participant data (IPD) sharing plan**IPD sharing plan summary**

Not provided at time of registration